1454.1: A Phase 1, open-label, dose-escalation study of a B7-H6/CD3 T-cell engager (BI 765049) with or without ezabenlimab (PD-1 inhibitor) in patients with advanced solid tumors expressing B7-H6^1,2

Zoom

1. NCT04752215. https://clinicaltrials.gov/ct2/show/NCT04752215. Accessed September 2023; 2. Falchook GS et al. ASCO 2022. Poster TPS3175.